Pharmaceuticals News and Research

RSS

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.

From Magstim 20 May 2015

New microscopy technique helps researchers to selectively visualize individual cells in living organism

Researchers at ETH Zurich's Department of Biosystems Science and Engineering in Basel have developed a new microscopy technique that enables for the first time to selectively visualize individual cells within the complex, three-dimensional tissue of a living organism.

20 May 2015

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

A new study by UCLA researchers has found that Naltrexone, a drug used to treat alcoholism, may also be a promising treatment for addiction to methamphetamine.

19 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

MedVantx launches MedStart Formulary Connect program for health systems and ACOs

MedVantx, Inc., a leading provider of point-of-care medication access, adherence and direct-to-patient consumer engagement programs, today announced the Company's MedStart Formulary Connect program. This innovative program equips leading health systems and ACOs with new formulary management tools that are designed to build greater alignment and advance the traditional medication formulary program upstream in the value chain to the point of care.

19 May 2015

Twin Cities Orthopedics joins Deterra partnership program to reduce prescription drug abuse and misuse

Verde Technologies announced that Golden Valley-based Twin Cities Orthopedics, the largest orthopedic group in Minnesota, has become its most recent partner in the fight against prescription drug abuse and misuse.

19 May 2015

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis.

19 May 2015

ORIG3N, LabCorp form strategic partnership

ORIG3N, Inc., a pioneer in regenerative medicine and provider of induced pluripotent stem cell (iPSC) storage, called LifeCapsule, today announced a strategic collaboration with Laboratory Corporation of America Holdings.

19 May 2015

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility.

19 May 2015

Two-drug combination improves lung function in some cystic fibrosis patients

The combination of two drugs — an investigational drug used in conjunction with an already FDA-approved medication — improved lung function in patients with one form of cystic fibrosis, according to two new studies.

19 May 2015

Frost & Sullivan honors industry leaders during 2015 Growth, Innovation & Leadership Awards Banquet

Frost & Sullivan presented thirty-five accolades to industry leaders and innovators during last Thursday's 2015 Growth, Innovation & Leadership Awards Banquet at the Royal Garden Hotel in Kensington, London.

19 May 2015

Experts team up to tackle a growing challenge to nuclear test monitoring

The world's experts in nuclear explosion monitoring teamed up with pharmaceutical producers from across the globe in Brussels, Belgium, from 12 to 14 May 2015, to address a growing challenge to nuclear test monitoring.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths.

19 May 2015

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals Inc. announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015.

18 May 2015

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

DC is a chronic condition affecting the hand in which abnormal buildup of collagen can cause the fingers to bend and be drawn in toward the palm...

18 May 2015

Fibromyalgia now considered as a lifelong central nervous system disorder

Fibromyalgia is the second most common rheumatic disorder behind osteoarthritis and, though still widely misunderstood, is now considered to be a lifelong central nervous system disorder, which is responsible for amplified pain that shoots through the body in those who suffer from it.

18 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.

15 May 2015

Drug combination lengthens lives of metastatic colorectal cancer patients

A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

15 May 2015

Pharmaceuticals News and Research

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

New microscopy technique helps researchers to selectively visualize individual cells in living organism

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

MedVantx launches MedStart Formulary Connect program for health systems and ACOs

Twin Cities Orthopedics joins Deterra partnership program to reduce prescription drug abuse and misuse

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

ORIG3N, LabCorp form strategic partnership

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Two-drug combination improves lung function in some cystic fibrosis patients

Frost & Sullivan honors industry leaders during 2015 Growth, Innovation & Leadership Awards Banquet

Experts team up to tackle a growing challenge to nuclear test monitoring

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

Fibromyalgia now considered as a lifelong central nervous system disorder

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

Drug combination lengthens lives of metastatic colorectal cancer patients

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring